MX2018012562A - Formulacion de granulos para administracion oral. - Google Patents

Formulacion de granulos para administracion oral.

Info

Publication number
MX2018012562A
MX2018012562A MX2018012562A MX2018012562A MX2018012562A MX 2018012562 A MX2018012562 A MX 2018012562A MX 2018012562 A MX2018012562 A MX 2018012562A MX 2018012562 A MX2018012562 A MX 2018012562A MX 2018012562 A MX2018012562 A MX 2018012562A
Authority
MX
Mexico
Prior art keywords
granule formulation
oral administration
granule
cariprazine hydrochloride
formulation
Prior art date
Application number
MX2018012562A
Other languages
English (en)
Inventor
Imada Yasushi
Ozaki Fuminori
Suzuki Akihiro
Mii Keiji
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of MX2018012562A publication Critical patent/MX2018012562A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a una formulación de gránulos que permite que el clorhidrato de cariprazina se almacene de manera estable. La solución proporciona una formulación de gránulos que contiene clorhidrato de cariprazina, en donde dicha formulación de gránulos contiene lactosa como diluyente primario.
MX2018012562A 2016-04-14 2017-04-13 Formulacion de granulos para administracion oral. MX2018012562A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16165247.4A EP3231418A1 (en) 2016-04-14 2016-04-14 Granule formulation for oral administration
PCT/IB2017/052129 WO2017178999A1 (en) 2016-04-14 2017-04-13 Granule formulation for oral administration

Publications (1)

Publication Number Publication Date
MX2018012562A true MX2018012562A (es) 2019-06-10

Family

ID=55802213

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012562A MX2018012562A (es) 2016-04-14 2017-04-13 Formulacion de granulos para administracion oral.

Country Status (13)

Country Link
US (1) US20190117647A1 (es)
EP (2) EP3231418A1 (es)
JP (1) JP2019511513A (es)
KR (1) KR20180131579A (es)
CN (1) CN109069429A (es)
AU (1) AU2017250640A1 (es)
BR (1) BR112018070615A2 (es)
CA (1) CA3020981A1 (es)
EA (1) EA201892235A1 (es)
IL (1) IL262204A (es)
MX (1) MX2018012562A (es)
TN (1) TN2018000326A1 (es)
WO (1) WO2017178999A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2317852T3 (en) 2008-07-16 2015-03-23 Richter Gedeon Nyrt PHARMACEUTICAL FORMULATIONS CONTAINING dopamine receptor ligands
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
US11273156B2 (en) * 2018-11-20 2022-03-15 Aurobindo Pharma Ltd Stable cariprazine formulations for oral use
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US11344503B2 (en) 2019-12-13 2022-05-31 Halo Science LLC Cariprazine release formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
EA023972B1 (ru) * 2008-02-21 2016-08-31 Рихтер Гедеон Нирт. Стабильный твёрдый препарат карипразина для перорального введения и способ его получения
DK2317852T3 (en) * 2008-07-16 2015-03-23 Richter Gedeon Nyrt PHARMACEUTICAL FORMULATIONS CONTAINING dopamine receptor ligands

Also Published As

Publication number Publication date
KR20180131579A (ko) 2018-12-10
EP3231418A1 (en) 2017-10-18
BR112018070615A2 (pt) 2019-02-05
IL262204A (en) 2018-11-29
WO2017178999A1 (en) 2017-10-19
JP2019511513A (ja) 2019-04-25
US20190117647A1 (en) 2019-04-25
EA201892235A1 (ru) 2019-03-29
TN2018000326A1 (en) 2020-01-16
CN109069429A (zh) 2018-12-21
AU2017250640A1 (en) 2018-11-08
CA3020981A1 (en) 2017-10-19
EP3442508A1 (en) 2019-02-20

Similar Documents

Publication Publication Date Title
SI3577110T1 (sl) 8-oksetan-3-IL-3,8-diazabiciklo(3.2.1)oktan-3-IL substituirane spojine kot zaviralci HIV-a
PH12018501096A1 (en) Modulators of chemokine receptors
TN2018000326A1 (en) Granule formulation for oral administration.
MA39749A (fr) Dérivés de pipéridine-dione
PH12017502237A1 (en) Nuclear receptor modulators
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
PH12018500903A1 (en) Pyranodipyridine compound
MX2021012440A (es) Farmacos precursores de oxabicicloheptanos.
EP3487475A4 (en) FORMULATION FOR MILD ANTICHOLINERGIC ANALOGS
EP3325487A4 (en) PREPARATION FOR MODERATE POTENTIAL ANTICHOLINERGIC ANALOGS
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
MX2018003903A (es) Compuesto biciclico y uso del mismo para inhibicion de suv39h2.
RS59873B1 (sr) Formulacija fosfomicina za parenteralnu primenu
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
EA201691924A1 (ru) Фармацевтические композиции
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
TW201612142A (en) Process for preparing 3-chloro-2-vinylphenol
MX2015012610A (es) Pacritinib deuterizado.
MX2018005376A (es) Derivados de azetidina para formacion de imágenes de tau.
MX2017004770A (es) Formas solidas del clorhidrato de nilotinib.
MX2017011391A (es) Procedimiento para la preparacion de clorhidrato de piperidina-4-carbotioamida.
UA107885U (uk) Застосування вінборону для профілактики гастропатії, індукованої ібупрофеном
IN2013CH05395A (es)